The present invention is directed to a method of enhancing TGF-beta signaling in a subject comprising administering to said subject a clathrin-dependent endocytosis inhibitor in an amount sufficient to enhance TGF-beta signaling. In another aspect, the invention is directed to a method of treating a condition associated with decreased TGF-beta signaling in a patient in need thereof comprising administering to said patient a clathrin-dependent endocytosis inhibitor in a therapeutically effective amount.
